Skip to content
vaccines hero image
vaccines hero image


Vaccines contain antigenic substances capable of inducing immunity against an infective agent or toxin.

They are frequently administered prophylactically but are increasingly being researched and developed in a therapeutic context (eg cancer vaccines which are designed to equip a patient’s immune system to treat an existing cancer).

While the global market for vaccines is less than 3% of the total pharmaceuticals market, World Health Organization research suggests that over the next few years, the vaccine market will enjoy a growth rate of 10% to 15% per year versus the 5% to 7% seen in the overall market.

To take a share of this expanding market, companies must navigate a number of challenges. The assessment, licensing and control of vaccines (which are biological medicinal products) occurs in an environment of rapid innovation and complex quality concerns. Our deep experience of vaccines, combined with the fact that our team includes lawyers with degrees in relevant scientific areas (molecular biology, biochemistry, genetics etc), enables us to quickly grasp evolving issues and technical concepts and provide nuanced and tailored advice.

We are trusted by many of the world’s leading vaccine companies to help them navigate all stages of the vaccine lifecycle.

News and insights

Person wearing protective clothing and holding apparatus in science lab

Blog Post: 03 April 2024

European Commission opens unprecedented abuse of dominance probe in animal medicines sector

The European Commission (EC) has opened a formal antitrust investigation into whether animal health company Zoetis has breached EU antitrust law by preventing the market launch of a competing novel…

Read more
Life Science

Blog Post: 28 March 2024

Czech Republic draws blood after English High Court finds serious irregularity in investment treaty arbitration award

The English High Court has upheld one of the Czech Republic’s challenges to an investment treaty award won by investors in a blood plasma business after finding that an UNCITRAL tribunal had failed to…

Read more
Six large cells and three small cells

Blog Post: 20 June 2022

Breaking: Global Covid-19 IPR waiver approved

Last Friday 17 June 2022, the WTO member states came to an agreement on the long negotiated TRIPS Waiver. In its annual 6 days conference (the Ministerial Conference), the WTO member states agreed…

Read more
Multiple test tubes and dropper

Blog Post: 03 May 2022

Potential compromise on Covid-19 IPR waiver: deadlock resolved?

Last month, a leaked document regarding the TRIPS Waiver revealed a breakthrough between the EU, South Africa, India and the United States. After 18 months of negotiations, the four parties now have…

Read more